BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

851 related articles for article (PubMed ID: 25111131)

  • 1. Current issues of RNAi therapeutics delivery and development.
    Haussecker D
    J Control Release; 2014 Dec; 195():49-54. PubMed ID: 25111131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of RNAi therapeutics: work in progress.
    Miller AD
    Expert Rev Med Devices; 2013 Nov; 10(6):781-811. PubMed ID: 24195461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of RNAi technology for targeted therapy--a track of siRNA based agents to RNAi therapeutics.
    Zhou Y; Zhang C; Liang W
    J Control Release; 2014 Nov; 193():270-81. PubMed ID: 24816071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells.
    Landesman-Milo D; Goldsmith M; Leviatan Ben-Arye S; Witenberg B; Brown E; Leibovitch S; Azriel S; Tabak S; Morad V; Peer D
    Cancer Lett; 2013 Jul; 334(2):221-7. PubMed ID: 22935680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of RNAi nanomedicines.
    Barros SA; Gollob JA
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1730-7. PubMed ID: 22732527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
    Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
    ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges.
    Won Lee J; Kyu Shim M; Kim H; Jang H; Lee Y; Hwa Kim S
    Adv Drug Deliv Rev; 2023 Oct; 201():115073. PubMed ID: 37657644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
    Martirosyan A; Olesen MJ; Howard KA
    Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies.
    Shajari N; Mansoori B; Davudian S; Mohammadi A; Baradaran B
    Curr Drug Deliv; 2017; 14(1):36-46. PubMed ID: 27538460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery vehicles for small interfering RNA in vivo.
    de Fougerolles AR
    Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of siRNA delivery to target sites: issues and future directions.
    Khalil IA; Yamada Y; Harashima H
    Expert Opin Drug Deliv; 2018 Nov; 15(11):1053-1065. PubMed ID: 30198792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference for therapy in the vascular endothelium.
    Kaufmann J; Ahrens K; Santel A
    Microvasc Res; 2010 Sep; 80(2):286-93. PubMed ID: 20144624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi using a chitosan/siRNA nanoparticle system: in vitro and in vivo applications.
    Andersen MØ; Howard KA; Kjems J
    Methods Mol Biol; 2009; 555():77-86. PubMed ID: 19495689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
    Huang X; Chau Y
    Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.